You are here

Article Text

Article menu
Download PDFPDF
DTB Select
Adverse effects
JCVI recommends extending HPV vaccination to boys

https://doi.org/10.1136/dtb.2019.000029

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Review of: Joint Committee on Vaccination and Immunisation. Statement on HPV vaccination. July 2018.

    Key learning point

    • The UK Joint Committee on Vaccination and Immunisation has advised that extending the human papillomavirus vaccine programme to include boys would be cost-effective.

    Updated evidence reviewed by the Joint Committee on Vaccination and Immunisation (JCVI) suggests that extending the human papillomavirus (HPV) vaccination programme to boys aged 11–13 years is cost-effective and should be introduced.1

    Overview

    In a review published in 2017, the JCVI concluded that it was unable to recommend the extension of the national HPV programme to adolescent boys.2 It noted that most of the benefit in boys can be obtained through achieving high uptake in the vaccination programme for girls. Following …

    View Full Text

    Footnotes

    • Contributors DTB team.

    • Provenance and peer review Commissioned; internally peer reviewed.